Jul 17, 2012
July 17, 2012- Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama (hereafter, “Chugai”)] announced that its research subsidiary ”Chugai Pharmabody Research Pte. Ltd.“ (“CPR”) has started its operation. CPR was establish in Singapore in January 2012 as a new company for conducting research focusing on the generation of new antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies.
Attached is a press release by CPR, distributed at its opening ceremony on July 13.